Results 51 to 60 of about 145,320 (184)

Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy

BMC Nephrology, 2018
Background Serum anti-phospholipase A2 receptor (PLA2R) antibody was correlated with disease activity of membranous nephropathy(MN). The predictive value of antibody titer changes on immunosuppressive response remains unknown.
Chao Li, Hang Li, Yu-bing Wen, Xue-mei Li, Xue-wang Li   +4 more
doaj   +1 more source

Anti-phospholipase A2 receptor antibodies directly induced podocyte damage in vitro

Renal Failure, 2022
Background The pathogenesis of primary membranous nephropathy (MN) involves the antibodies against antigens on the cell surface of podocytes, with the majority of M-type phospholipase A2 receptor (PLA2R), and a profound podocyte dysfunction.
Yanfen Li, Juntao Yu, Miao Wang, Zhao Cui, Ming-hui Zhao   +4 more
doaj   +1 more source

A membranous nephropathy variant mimicking minimal change disease

The Journal of Pathology: Clinical Research, Volume 12, Issue 1, January 2026.
Abstract This study characterizes a novel disease pattern of membranous nephropathy (MN) that exhibits overlapping clinicopathological features with minimal change disease (MCD), termed ‘MCD‐like MN’. Patients with histologically confirmed MN showing sparse and segmental subepithelial electron‐dense deposits (EDD) but clinically resembling MCD were ...
Chuqi Pan, Silin Xiang, Mengya Jiang, Yuan Li, Biao Huang, Tian Ye, Yuanyuan Du, Xuanli Tang, Yuan Yuan   +8 more
wiley   +1 more source

Presence of M-type Phospholipase A2 Receptor Antibody in Membranous Nephropathy

Turkish Journal of Nephrology, 2020
Objective: The presence of autoantibodies against M-type phospholipase A2 receptor (anti-PLA2R) is a characteristic of idiopathic membranous nephropathy (IMN).
Özgür Akın Oto, Halil Yazıcı, Yaşar Çalışkan, Ayşe Serra Artan, Mehmet Şükrü Sever, Egemen Cebeci, Savaş Öztürk, Aydın Türkmen   +7 more
doaj   +1 more source

Always Consider a Repeat Kidney Biopsy: Acute Interstitial Nephritis Soon After Membranous Nephropathy

Case Reports in Nephrology, Volume 2026, Issue 1, 2026.
Introduction The heterogeneity of membranous nephropathy is well described in the literature, and its clinical course and response to treatment vary. Similarly, acute interstitial nephritis (AIN) can present in unexpected and unusual ways and should always be considered within the differential diagnosis of worsening renal function.
Jarrad Hopkins, James Nolan, Maleeka Ladhani, Chiang Lee, Poulami Jha   +4 more
wiley   +1 more source

Qualitative and Quantitative Dosage of the Anti M-Type Phospholipase A2 Receptor Autoantibody: One-Year Experience in Quebec’s Reference Center

Canadian Journal of Kidney Health and Disease, 2021
Background: Quantification of the M-type phospholipase A2 receptor antibodies (anti-PLA2R) is now an essential tool for diagnosis and management of primary membranous nephropathy (MN).
Simon Leclerc, Karim Benkirane, Annie-Claire Nadeau-Fredette, Naoual Elftouh, Jean-Philippe Lafrance, Vincent Pichette, Virginie Royal, Caroline Lamarche, Louis-Philippe Laurin   +8 more
doaj   +1 more source

Diagnostic Complexity in Differentiating Between Primary and Secondary Anti‐PLA2R–Positive Membranous Nephropathy in a Patient With Laryngeal Squamous Cell Carcinoma

Case Reports in Nephrology, Volume 2026, Issue 1, 2026.
Introduction The association between membranous nephropathy (MN) and malignant neoplasms has been extensively studied in recent decades and is well established in the literature. Although PLA2R is the main target antigen in primary MN, there remain uncertainties regarding a possible connection between malignancy and anti‐PLA2R positivity.
Fabiano Bichuette Custodio, Laura Penna Rocha, Luciana Botta Ribeiro, Marlene Antônia dos Reis, Juliana Reis Machado, Poorani Gurumallesh Prabu   +5 more
wiley   +1 more source

Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

, 2023
Background The currently recommended dose of rituximab for primary membranous nephropathy is as high as that for lymphoma. However, the clinical manifestations of membranous nephropathy vary widely.
Song Wang, Wenhan Bao, Sijia Zhou, Yue Wang, Zhuan Cui, Danxia Zheng, Zhenling Deng   +6 more
core   +1 more source

Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome

Frontiers in Pharmacology, 2022
Rituximab is one of the first-line therapies for patients with membranous nephropathy (MN) at high risk of progression towards kidney failure. We investigated whether the response to Rituximab was affected by sex and anti-PLA2R antibody levels in 204 ...
Annalisa Perna, Barbara Ruggiero, Manuel Alfredo Podestà, Manuel Alfredo Podestà, Luca Perico, Silvia Orisio, Hanna Debiec, Giuseppe Remuzzi, Piero Ruggenenti, Piero Ruggenenti   +9 more
doaj   +1 more source

Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)

, 2016
Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN.
Stellato, Tiziana, Napodano, Pietro, Londrino, Francesco, Ortisi, Giuseppe, Radice, Antonella, Sinico, Renato Alberto, Trezzi, Barbara, Maggiore, Umberto, Pesce, Gianpaola, D'Amico, Marco, Ravera, Federica, Santoro, Domenico, Pregnolato, Francesca, Rolla, Davide   +13 more
core   +2 more sources